A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis EGPA

NCT05979051

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	Guangdong Hengrui Pharmaceutical Co., Ltd
Enrollment	166 participants

Key Eligibility Criteria

Inclusion (5)

- Male or female subjects age 18 years or older;
- Diagnosed with EGPA for at least 6 months;
- History of relapsing or refractory EGPA
- Stable dose of oral prednisone of e7.5 mg/day (but not \>50 mg/day) for at least 4 weeks prior to randomization;
- If receiving immunosuppressive therapy (excluding cyclophosphamide), the dosage must be stable within 4 weeks prior to randomization and during the study.

Exclusion (22)

- Subjects with other eosinophilic-related diseases;
- Diagnosed with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
- Life-threatening EGPA within 3 months prior to randomization;
- Malignancy history within 5 years prior to randomization;
- Immunodeficiency;

... and 17 more (see full listing online)

Locations (2 total)

Beijing Hospital, Beijing, Beijing Municipality, China
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China